The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 3, 2015, Pages 494-508

  Dick, Taryn E ^a   Hengst, Jeremy A ^a   Fox, Todd E ^b   Colledge, Ashley L ^a   Kale, Vijay P ^a   Sung, Shen Shu ^a   Sharma, Arun ^a   Amin, Shantu ^a   Loughran, Thomas P ^c   Kester, Mark ^b   Wang, Hong Gang ^a   Yun, Jong K ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; COLCHICINE; CYCLIN DEPENDENT KINASE 1; ENZYME INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANT PROTEIN 1; N' [1 (3,4 DIMETHOXYPHENYL)ETHYLIDENE] 3 (4 METHOXXYPHENYL) 1H PYRAZOLE 5 CARBOHYDRAZIDE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; SPHINGOSINE KINASE 1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VINCRISTINE; HYDRAZINE DERIVATIVE; N'-((1E)-1-(3,4-DIMETHOXYPHENYL)ETHYLIDENE)-3-(4-METHOXYPHENYL)-1H-PYRAZOLE-5-CARBOHYDRAZIDE; PHOSPHOTRANSFERASE; PYRAZOLE DERIVATIVE; SPHINGOSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOSIS; MULTIDRUG RESISTANCE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HL 60 CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; U937 CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; HYDRAZINES; LEUKEMIA, MYELOID, ACUTE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PYRAZOLES; U937 CELLS;

EID: 84921528903     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.219659     Document Type: Article

References (100)

1. Adan-Gokbulut A, Kartal-Yandim M, Iskender G, and Baran Y (2013) Novel agents targeting bioactive sphingolipids for the treatment of cancer. Curr Med Chem 20: 108-122.
2. Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, Juin P, and Barillé-Nion S (2014) Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis 5:e1291.
3. Baran Y, Gunduz U, and Ural AU (2006) Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Exp Oncol 28:163-165.
4. Barboule N, Truchet I, and Valette A (2005) Localization of phosphorylated forms of Bcl-2 in mitosis: co-localization with Ki-67 and nucleolin in nuclear structures and on mitotic chromosomes. Cell Cycle 4:590-596.
5. Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, Claxton DF, and Yun JK (2008) Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma 49:948-954.
6. Beverly LJ, Howell LA, Hernandez-Corbacho M, Casson L, Chipuk JE, and Siskind LJ (2013) BAK activation is necessary and sufficient to drive ceramide synthasedependent ceramide accumulation following inhibition of BCL2-like proteins. Biochem J 452:111-119.
7. Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, and Cuvillier O (2006) Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20:95-102.
8. Bonnaud S, Niaudet C, Legoux F, Corre I, Delpon G, Saulquin X, Fuks Z, Gaugler MH, Kolesnick R, and Paris F (2010) Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res 70:9905-9915.
9. Bostock CJ, Prescott DM, and Kirkpatrick JB (1971) An evaluation of the double thymidine block for synchronizing mammalian cells at the G1-S border. Exp Cell Res 68:163-168.
10. Broxterman HJ and Schuurhuis GJ (1997) Transport proteins in drug resistance: detection and prognostic significance in acute myeloid leukemia. J Intern Med Suppl 740:147-151.
11. Cagnol S and Chambard JC (2010) ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 277:2-21.
12. Chan KS, Koh CG, and Li HY (2012) Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis 3:e411.
13. Chow JP, Poon RY, and Ma HT (2011) Inhibitory phosphorylation of cyclindependent kinase 1 as a compensatory mechanism for mitosis exit. Mol Cell Biol 31:1478-1491.
14. Chu R, Terrano DT, and Chambers TC (2012) Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration. Biochem Pharmacol 83:199-206.
15. Cianfriglia M (2013) Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML). Ann Ist Super Sanita 49:190-208.
16. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, et al. (2004) Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10:3371-3376.
17. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, and Spiegel S (1996) Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381:800-803.
18. Dai H, Ding H, Meng XW, Lee SH, Schneider PA, and Kaufmann SH (2013) Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res 73:6998-7008.
19. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, and May WS, Jr (2001) Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 276:23681-23688.
20. Ding J, Swain JE, and Smith GD (2011) Aurora kinase-A regulates microtubule organizing center (MTOC) localization, chromosome dynamics, and histone-H3 phosphorylation in mouse oocytes. Mol Reprod Dev 78:80-90.
21. Du L, Lyle CS, and Chambers TC (2005) Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 24:107-117.
22. Du L, Lyle CS, Obey TB, Gaarde WA, Muir JA, Bennett BL, and Chambers TC (2004) Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNKindependent. J Biol Chem 279 : 11957-11966.
23. Eichhorn JM, Sakurikar N, Alford SE, Chu R, and Chambers TC (2013) Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death. Cell Death Dis 4: e834.
24. Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA, and Chambers TC (2000) Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 275:29980-29985.
25. Fletcher L, Cheng Y, and Muschel RJ (2002) Abolishment of the Tyr-15 inhibitory phosphorylation site on cdc2 reduces the radiation-induced G(2) delay, revealing a potential checkpoint in early mitosis. Cancer Res 62: 241-250.
26. Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY, Jefferson LS, Kim JK, Bronson SK, Flanagan JM, et al. (2011) Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res 52:509-517.
27. Francy JM, Nag A, Conroy EJ, Hengst JA, and Yun JK (2007) Sphingosine kinase 1 expression is regulated by signaling through PI3K, AKT2, and mTOR in human coronary artery smooth muscle cells. Biochim Biophys Acta 1769:253-265.
28. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, and Smith CD (2006) Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 318:596-603.
29. Funato T, Harigae H, Abe S, and Sasaki T (2004) Assessment of drug resistance in acute myeloid leukemia. Expert Rev Mol Diagn 4:705-713.
30. Gillies L, Lee SC, Long JS, Ktistakis N, Pyne NJ, and Pyne S (2009) The sphingosine 1-phosphate receptor 5 and sphingosine kinases 1 and 2 are localised in centrosomes: possible role in regulating cell division. Cell Signal 21:675-684.
31. Goetzl EJ, Kong Y, and Mei B (1999) Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 162 :2049-2056.
32. Grösch S, Schiffmann S, and Geisslinger G (2012) Chain length-specific properties of ceramides. Prog Lipid Res 51:50-62.
33. Guan H, Liu L, Cai J, Liu J, Ye C, Li M, and Li Y (2011) Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer. Mol Endocrinol 25:1858-1866.
34. Haldar S, Basu A, and Croce CM (1998) Serine-70 is one of the critical sites for druginduced Bcl2 phosphorylation in cancer cells. Cancer Res 58:1609-1615.
35. Hannun YA and Luberto C (2000) Ceramide in the eukaryotic stress response. Trends Cell Biol 10:73-80.
36. Harley ME, Allan LA, Sanderson HS, and Clarke PR (2010) Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 29:2407-2420.
37. Hartmann D, Lucks J, Fuchs S, Schiffmann S, Schreiber Y, Ferreirós N, Merkens J, Marschalek R, Geisslinger G, and Grösch S (2012) Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int J Biochem Cell Biol 44:620-628.
38. Heffernan-Stroud LA and Obeid LM (2013) Sphingosine kinase 1 in cancer. Adv Cancer Res 117:201-235.
39. Heijink AM, Krajewska M, and van Vugt MA (2013) The DNA damage response during mitosis. Mutat Res 750:45-55.
40. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, Bazett-Jones DP, and Allis CD (1997) Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106:348-360.
41. Hengst JA, Wang X, Sk UH, Sharma AK, Amin S, and Yun JK (2010) Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett 20 :7498-7502.
42. Holohan C, Van Schaeybroeck S, Longley DB, and Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714-726.
43. Jarvis WD, Fornari FA, Jr, Auer KL, Freemerman AJ, Szabo E, Birrer MJ, Johnson CR, Barbour SE, Dent P, and Grant S (1997) Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol Pharmacol 52:935-947.
44. Kelkel M, Cerella C, Mack F, Schneider T, Jacob C, Schumacher M, Dicato M, and Diederich M (2012) ROS-independent JNK activation and multisite phosphorylation of Bcl-2 link diallyl tetrasulfide-induced mitotic arrest to apoptosis. Carcinogenesis 33:2162-2171.
45. Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, East JE, Houck JD, Lynch KR, and Macdonald TL (2011) Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem 54:3524-3548.
46. Kennedy SG, Wagner AJ, Conzen SD, Jordán J, Bellacosa A, Tsichlis PN, and Hay N (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11:701-713.
47. Kim HJ, Oh JE, Kim SW, Chun YJ, and Kim MY (2008) Ceramide induces p38 MAPK-dependent apoptosis and Bax translocation via inhibition of Akt in HL-60 cells. Cancer Lett 260:88-95.
48. Kim JA, Lee J, Margolis RL, and Fotedar R (2010) SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene 29:1702-1716.
49. Knapp P, Baranowski M, Knapp M, Zabielski P, B?achnio-Zabielska AU, and Górski J (2010) Altered sphingolipid metabolism in human endometrial cancer. Prostaglandins Other Lipid Mediat 92:62-66.
50. Kotelevets N, Fabbro D, Huwiler A, and Zangemeister-Wittke U (2012) Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis. PLoS ONE 7:e39209.
51. Koybasi S, Senkal CE, Sundararaj K, Spassieva S, Bielawski J, Osta W, Day TA, Jiang JC, Jazwinski SM, Hannun YA, et al. (2004) Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem 279:44311-44319.
52. Kumar CC (2011) Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2:95-107.
53. Kwon YG, Min JK, Kim KM, Lee DJ, Billiar TR, and Kim YM (2001) Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production. J Biol Chem 276:10627-10633.
54. Laviad EL, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill AH, Jr, and Futerman AH (2008) Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 283:5677-5684.
55. Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, Levade T, and Moreau-Gachelin F (2005) Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 106:1808-1816.
56. Li QF, Huang WR, Duan HF, Wang H, Wu CT, and Wang LS (2007) Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene 26:7904-7908.
57. Licht T, Goldenberg SK, Vieira WD, Gottesman MM, and Pastan I (2000) Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice. Gene Ther 7: 348-358.
58. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, and Shen Y (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26:3972-3979.
59. Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, and Robertson GP (2012) Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res 25:259-274.
60. Malavaud B, Pchejetski D, Mazerolles C, de Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P, and Cuvillier O (2010) Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer 46: 3417-3424.
61. Marquardt D, McCrone S, and Center MS (1990) Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 50:1426-1430.
62. Morgan DO (1995) Principles of CDK regulation. Nature 374:131-134.
63. Mukhtar E, Adhami VM, and Mukhtar H (2014) Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther 13:275-284.
64. Oh HL, Seok JY, Kwon CH, Kang SK, and Kim YK (2006) Role of MAPK in ceramideinduced cell death in primary cultured astrocytes from mouse embryonic brain. Neurotoxicology 27:31-38.
65. Oktay K, Buyuk E, Oktem O, Oktay M, and Giancotti FG (2008) The c-Jun N-terminal kinase JNK functions upstream of Aurora B to promote entry into mitosis. Cell Cycle 7:533-541.
66. Orr Gandy KA and Obeid LM (2013) Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. Biochim Biophys Acta 1831:157-166.
67. Park JW, Park WJ, and Futerman AH (2014) Ceramide synthases as potential targets for therapeutic intervention in human diseases. Biochim Biophys Acta 1841: 671-681.
68. Paugh BS, Bryan L, Paugh SW, Wilczynska KM, Alvarez SM, Singh SK, Kapitonov D, Rokita H, Wright S, Griswold-Prenner I, et al. (2009) Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol Chem 284: 3408-3417.
69. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S, et al. (2008) A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112:1382-1391.
70. Petrache I, Kamocki K, Poirier C, Pewzner-Jung Y, Laviad EL, Schweitzer KS, Van Demark M, Justice MJ, Hubbard WC, and Futerman AH (2013) Ceramide synthases expression and role of ceramide synthase-2 in the lung: insight from human lung cells and mouse models. PLoS ONE 8:e62968.
71. Pitson SM, Powell JA, and Bonder CS (2011) Regulation of sphingosine kinase in hematological malignancies and other cancers. Anticancer Agents Med Chem 11: 799-809.
72. Ricci C, Onida F, Servida F, Radaelli F, Saporiti G, Todoerti K, Deliliers GL, and Ghidoni R (2009) In vitro anti-leukaemia activity of sphingosine kinase inhibitor. Br J Haematol 144:350-357.
73. Sakurikar N, Eichhorn JM, Alford SE, and Chambers TC (2014) Identification of a mitotic death signature in cancer cell lines. Cancer Lett 343:232-238.
74. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, and Pietenpol JA (1998) Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 273:30777-30784.
75. Seefelder W, Schwerdt G, Freudinger R, Gekle M, and Humpf HU (2002) Liquid chromatography/electrospray ionisation-mass spectrometry method for the quantification of sphingosine and sphinganine in cell cultures exposed to fumonisins. J Chromatogr B Analyt Technol Biomed Life Sci 780:137-144.
76. Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, Furuhata A, Takagi A, Kojima T, Nakamura M, et al. (2008) Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int J Hematol 87:266-275.
77. Spiegel S and Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4:397-407.
78. Sullards MC and Merrill AH, Jr (2001) Analysis of sphingosine 1-phosphate, ceramides, and other bioactive sphingolipids by high-performance liquid chromatographytandem mass spectrometry. Sci STKE 2001:1-11.
79. Sweet K and Lancet JE (2014) Novel therapeutics in acute myeloid leukemia. Curr Hematol Malig Rep 9:109-117.
80. Taha TA, Mullen TD, and Obeid LM (2006) A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta 1758:2027-2036.
81. Terrano DT, Upreti M, and Chambers TC (2010) Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 30:640-656.
82. Topham CH and Taylor SS (2013) Mitosis and apoptosis: how is the balance set? Curr Opin Cell Biol 25:780-785.
83. Tóthová E, Fricova M, Stecová N, Kafková A, and Elbertová A (2002) High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma 49:141-144.
84. Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S, and Chambers TC (2008) Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 283:35517-35525.
85. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, and Prior TW (2005) Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64:695-705.
86. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399.
87. Van Horn RD, Chu S, Fan L, Yin T, Du J, Beckmann R, Mader M, Zhu G, Toth J, Blanchard K, et al. (2010) Cdk1 activity is required for mitotic activation of aurora A during G2/M transition of human cells. J Biol Chem 285:21849-21857.
88. Vassilev LT (2006) Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1. Cell Cycle 5:2555-2556.
89. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, et al. (1996) Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380:75-79.
90. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, Shehata S, Kung AL, Beroukhim R, and Golub TR (2012) Chemical genomics identifies small-moleculeMCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 21:547-562.
91. Welburn JP, Tucker JA, Johnson T, Lindert L, Morgan M, Willis A, Noble ME, and Endicott JA (2007) How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. J Biol Chem 282:3173-3181.
92. Westwick JK, Bielawska AE, Dbaibo G, Hannun YA, and Brenner DA (1995) Ceramide activates the stress-activated protein kinases. J Biol Chem 270:22689-22692.
93. Wu J, Spiegel S, and Sturgill TW (1995) Sphingosine 1-phosphate rapidly activates the mitogen-activated protein kinase pathway by a G protein-dependent mechanism. J Biol Chem 270:11484-11488.
94. Xia Z, Dickens M, Raingeaud J, Davis RJ, and Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331.
95. Yamamoto K, Ichijo H, and Korsmeyer SJ (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19:8469-8478.
96. Yang JM, Yang GY, Medina DJ, Vassil AD, Liao J, and Hait WN (1999) Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. Biochem Biophys Res Commun 266:167-173.
97. Yecies D, Carlson NE, Deng J, and Letai A (2010) Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115:3304-3313.
98. Yoon CH, Kim MJ, Park MT, Byun JY, Choi YH, Yoo HS, Lee YM, Hyun JW, and Lee SJ (2009) Activation of p38 mitogen-activated protein kinase is required for death receptor-independent caspase-8 activation and cell death in response to sphingosine. Mol Cancer Res 7:361-370.
99. Zhao X, Yang L, Hu J, and Ruan J (2010) miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 34:1078-1082.
100. Zhou L, Cai X, Han X, Xu N, and Chang DC (2014) CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2/Bax family proteins during treatment with microtubule interfering agents. Cell Biol Int 38:737-746.